Diana Glaccum-Gavagni
Psychiatry · Pembroke Pines, FLNPI 1801097001
Payments from drug & device makers
Across 209 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$709
- Sunovion Pharmaceuticals Inc.$641
- Otsuka America Pharmaceutical, Inc.$549
- Bausch Health US, LLC$268
- Takeda Pharmaceuticals U.S.A., Inc.$241
- Supernus Pharmaceuticals, Inc.$177
- plus $1K from 14 others
What the payments were for
- Food & beverage$3,690100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $709 |
| Sunovion Pharmaceuticals Inc. | 50 | $641 |
| Otsuka America Pharmaceutical, Inc. | 31 | $549 |
| Bausch Health US, LLC | 14 | $268 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $241 |
| Supernus Pharmaceuticals, Inc. | 4 | $177 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 9 | $171 |
| Vanda Pharmaceuticals Inc. | 5 | $140 |
| Alkermes, Inc. | 7 | $138 |
| Lundbeck LLC | 6 | $128 |
| Almatica Pharma LLC | 5 | $85 |
| Ironshore Pharmaceuticals Inc. | 4 | $83 |
| Teva Pharmaceuticals USA, Inc. | 3 | $73 |
| Shire North American Group Inc | 4 | $72 |
| Corium, LLC | 4 | $62 |
| Tris Pharma Inc | 3 | $53 |
| Idorsia Pharmaceuticals US Inc | 2 | $48 |
| Johnson & Johnson | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- QELBREE$125
How this compares
$3,690 in reported general payments places this provider in the 75th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lurasidone Hcl | 24 | $13,322 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,914 |
| Duloxetine Hcl | 52 | $937 |
| Bupropion XlBupropion Hcl | 54 | $762 |
| Olanzapine | 11 | $656 |
| Clonazepam | 73 | $498 |
| Alprazolam | 77 | $448 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $436 |
| Topiramate | 16 | $394 |
| Lorazepam | 65 | $375 |
| Amitriptyline Hcl | 18 | $355 |
| Gabapentin | 42 | $349 |
| Fluoxetine Hcl | 25 | $317 |
| Lamotrigine | 27 | $300 |
| Doxepin Hcl | 23 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $241 | $5,91412 claims |
| Almatica Pharma LLCSertraline Hcl | $85 | $19022 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Pembroke Pines
- Patrick PinchinatPembroke Pines$1.6M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
- Patricia JunqueraMiami$10.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.